Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–202 of 202 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Influenza Type A Clear all

Conditions: Cancer
Interventions: Non-Interventional; Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Influenza
Interventions: Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 17 Years
Enrollment: 583 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Baltimore, Maryland • Kansas City, Missouri • St Louis, Missouri + 6 more

Conditions: Influenza
Interventions: Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, MF59; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 64 Years
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Decatur, Georgia • Iowa City, Iowa • Cincinnati, Ohio + 1 more

Conditions: Influenza
Interventions: Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 65 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 4 more

Conditions: Influenza
Interventions: Ca/04/2009/H1N1 Vero Grown Challenge Virus; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections, H1N1 Influenza Virus
Interventions: Influenza A (H1N1) monovalent vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 29
States / cities: Alhambra, California • La Jolla, California • Long Beach, California + 22 more

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine, Trivalent Baculovirus-expressed Influenza HA vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: Baloxavir Marboxil, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 5 Years to 64 Years
Enrollment: 4,138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 43
States / cities: Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 32 more

Conditions: Influenza
Interventions: Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed); Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 4
States / cities: Baltimore, Maryland • Rochester, New York • Durham, North Carolina + 1 more

Conditions: Influenza A
Interventions: Pimodivir 600 mg, Placebo, SOC Treatment; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 13 Years to 85 Years
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 28
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Fresno, California + 23 more

Search by objective public record fields.

Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells

Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels

H7N9 Mix and Match With MF59 in Healthy Adults

H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults

Influenza A 2009 H1N1 Challenge Study in Healthy Adults

Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women

Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma

Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households

H5 Vaccine Alone or With Adjuvant in Healthy Adults

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection